Pleiotropic effect of pyridoxamine on diabetic complications via CD36 expression in KK-Ay/Ta mice

Diabetes Research and Clinical Practice

Volumn 83, Issue 2, 2009, Pages 183-189

  Murakoshi, Maki ^a   Tanimoto, Mitsuo ^a   Gohda, Tomohito ^a   Hagiwara, Shinji ^a   Ohara, Ikko ^a   Toyoda, Hitoe ^a   Ishikawa, Yuji ^a   Horikoshi, Satoshi ^a   Tomino, Yasuhiko ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CD36; Pyridoxamine

Indexed keywords

ALBUMIN; CD36 ANTIGEN; CREATININE; INSULIN; MALONALDEHYDE; PYRIDOXAMINE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; CREATININE URINE LEVEL; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; MALE; MICROSCOPY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLEIOTROPY; PROTEIN URINE LEVEL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ADIPOSE TISSUE; ANIMALS; ANTIGENS, CD36; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; KIDNEY; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; PYRIDOXAMINE;

EID: 58249110786     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.11.008     Document Type: Article

References (22)

1. Brownlee M., Vlassara H., Kooney A., Ulrich P., and Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232 (1986) 1629-1632
2. Singh R., Barden A., Mori T., and Beilin L. Advanced glycation end-products: a review. Diabetologia 44 (2001) 129-146
3. Khalifah R.G., Baynes J.W., and Hudson B.G. Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem. Biophys. Res. Commun. 257 (1999) 251-258
4. Degenhardt T.P., Alderson N.L., Arrington D.D., Beattie R.J., Basgen J.M., Steffes M.W., et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int. 61 (2002) 939-950
5. Onorato J.M., Jenkins A.J., Thorpe S.R., and Baynes J.W. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. J. Biol. Chem. 275 (2000) 21177-21184
6. Jain S.K., and Lim G. Pyridoxine and pyridoxamine inhibits superoxide radicals and prevents lipid peroxidation, protein glycosylation, and (Na+ + K+)-ATPase activity reduction in high glucose-treated human erythrocytes. Free Radic. Biol. Med. 30 (2001) 232-237
7. Chetyrkin S.V., Mathis M.E., Ham A.J., Hachey D.L., Hudson B.G., and Voziyan P.A. Propagation of protein glycation damage involves modification of tryptophan residues via reactive oxygen species: inhibition by pyridoxamine. Free Radic. Biol. Med. 44 (2008) 1276-1285
8. Horiuchi S., Sakamoto Y., and Sakai M. Scavenger receptors for oxidized and glycated proteins. Amino Acids 25 (2003) 283-292
9. Endemann G., Stanton L.W., Madden K.S., Bryant C.M., White R.T., and Protter A.A. CD36 is a receptor for oxidized low density lipoprotein. J. Biol. Chem. 268 (1993) 11811-11816
10. Abumrad N., Harmon C., and Ibrahimi A. Membrane transport of long-chain fatty acids: evidence for a facilitated process. J. Lipid Res. 39 (1998) 2309-2318
11. Abumrad N.A., el-Maghrabi M.R., Amri E.Z., Lopez E., and Grimaldi P.A. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. J. Biol. Chem. 268 (1993) 17665-17668
12. Furuhashi M., Ura N., Nakata T., and Shimamoto K. Insulin sensitivity and lipid metabolism in human CD36 deficiency. Diabetes Care 26 (2003) 471-474
13. Kuniyasu A., Ohgami N., Hayashi S., Miyazaki A., Horiuchi S., and Nakayama H. CD36-mediated endocytic uptake of advanced glycation end products (AGE) in mouse 3T3-L1 and human subcutaneous adipocytes. FEBS Lett. 537 (2003) 85-90
14. Ito T., Tanimoto M., Yamada K., Kaneko S., Matsumoto M., Obayashi K., et al. Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy. Nephrology (Carlton) 11 (2006) 29-35
15. Usui S., Hara Y., Hosaki S., and Okazaki M. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J. Lipid Res. 43 (2002) 805-814
16. Takatori A., Ishii Y., Itagaki S., Kyuwa S., and Yoshikawa Y. Amelioration of the beta-cell dysfunction in diabetic APA hamsters by antioxidants and AGE inhibitor treatments. Diabetes Metab. Res. Rev. 20 (2004) 211-218
17. Coburn C.T., Knapp Jr. F.F., Febbraio M., Beets A.L., Silverstein R.L., and Abumrad N.A. Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice. J. Biol. Chem. 275 (2000) 32523-32529
18. Pravenec M., Landa V., Zidek V., Musilova A., Kren V., Kazdova L., et al. Transgenic rescue of defective Cd36 ameliorates insulin resistance in spontaneously hypertensive rats. Nat. Genet. 27 (2001) 156-158
19. Lewis G.F., Carpentier A., Adeli K., and Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr. Rev. 23 (2002) 201-229
20. Susztak K., Bottinger E., Novetsky A., Liang D., Zhu Y., Ciccone E., et al. Molecular profiling of diabetic mouse kidney reveals novel genes linked to glomerular disease. Diabetes 53 (2004) 784-794
21. Chen Z., Ishibashi S., Perrey S., Osuga J.i., Gotoda T., Kitamine T., et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 372-377
22. Tanimoto M., Gohda T., Kaneko S., Hagiwara S., Murakoshi M., Aoki T., et al. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice. Metabolism 56 (2007) 160-167